Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7036 to 7050 of 7707 results

  1. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Technology appraisal guidance
    Published
    27 August 2003

  2. Fremanezumab for preventing migraine (TA631)

    This guidance has been updated and replaced by NICE technology appraisal guidance 764.

    Technology appraisal guidance
    Published
    3 June 2020

  3. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Technology appraisal guidance
    Published
    14 August 2019

  4. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.

    Technology appraisal guidance
    Published
    28 August 2019

  5. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Technology appraisal guidance
    Published
    26 June 2000

  6. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Technology appraisal guidance
    Last updated
    1 August 2015

  7. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

    This guidance has been updated and replaced by NICE technology appraisal guidance 770.

    Technology appraisal guidance
    Published
    11 September 2019

  8. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

    Technology appraisal guidance
    Published
    25 September 2019

  9. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79. 

    Technology appraisal guidance
    Published
    26 November 2003

  10. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)

    This guidance has been updated and replaced by NICE technology appraisal guidance 835.

    Technology appraisal guidance
    Published
    7 January 2022

  11. Newer drugs for epilepsy in adults (TA76)

    This guideline has been updated and replaced by NICE guideline CG137.

    Technology appraisal guidance
    Published
    24 March 2004

  12. Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)

    NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.

    Technology appraisal guidance
    Published
    3 November 2021

  13. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    25 May 2005

  14. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)

    This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.

    Technology appraisal guidance
    Published
    24 August 2005

  15. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Technology appraisal guidance
    Published
    23 August 2000